Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US11338027B2 · kind B2 · utility
4Cited by
17References
44Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 25, 2020 |
| Grant date | May 24, 2022 |
| Priority date | — |
| Expiry date | Nov 25, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/82
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.